Imbruvica first therapy for rare blood cancer WM in Europe
A type of non-Hodgkin lymphoma, WM usually gets worse slowly over time and causes abnormal blood cells to grow within the bone marrow, lymph nodes, liver and spleen. Abnormal B-cells also overproduce proteins that can cause excess bleeding and problems with vision and the nervous system. Janssen-Cilag’s Imbruvica has become the first therapy to be